Back to top

gene-therapy: Archive

Zacks Equity Research

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

INONegative Net Change CRMDPositive Net Change KNSAPositive Net Change PGENPositive Net Change

Zacks Equity Research

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

REGNPositive Net Change CRMDPositive Net Change NTLAPositive Net Change IMCRPositive Net Change